William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...

Company AnnouncementJohnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture ...

“With EPKINLY® (epcoritamab) moving from strength to strength and two wholly owned assets, rinatabart sesutecan (Rina-S™) and acasunlimab in Phase 3 development, we are confident in the ...

Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...

We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other cash-rich ...

In that indication, the drug competes with AbbVie and Genmab’s rival CD20xCD3 bispecific Epkinly (epcoritamab), so moving it into the first relapse setting could hand Roche an advantage.

Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise ...

We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other cash-rich ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...